Atopic eczema (also known as atopic dermatitis) is a chronic inflammatory skin condition characterised by intense itching, dry skin, erythema, inflammation and sometimes exudation.1-3 It is typically an episodic disease of exacerbations and remissions.1 In some cases it may be continuous.1 Acute lesions are itchy +/- painful and erythematous; there may be tiny vesicles that ooze and crust. The subsequent chronic inflammatory phase is characterised by scaling, excoriations, skin thickening and enhancement of skin markings (lichenification).4,5

Atopic eczema affects mainly the flexor surfaces of the elbows and knees, as well as the face and neck;3 although patterns of localisation can differ depending on the age of the patient. In babies and small children eczema is common on the cheeks, forehead and extensor surfaces of the limbs.3

**The impact of atopic eczema**

Although atopic eczema may not always be recognised as being a serious medical condition, the impact of atopic eczema on quality of life can be considerable, and varies according to disease severity.3 The effects of atopic eczema vary in complexity from a minor irritating rash to a complex, long-term condition which can be a major challenge to living a “normal” life. In addition to the burden imposed by daily treatment, the condition affects everyday activities such as work, school and social relationships.3 People with atopic eczema may also experience anxiety, depression and other psychological problems.3 Sleep disturbance is common, especially during flares, which in turn can lead to problems with irritability and lack of concentration.3 In children, sleeplessness and irritability could be perceived as hyperactivity.7

**Prevalence of atopic eczema**

Estimates of the prevalence of atopic eczema vary but it is thought that the condition:
- has no difference in prevalence based on gender or ethnicity1,19
- typically starts early in life, with about 80% of cases starting before the age of 5 years2,8,11,20-22
- is mild in around 80% of cases; only around 2-4% of people with eczema have a severe form of the disease.3

**Aetiology of eczema (updated 2016)**

The pathophysiology of atopic eczema is not fully understood but is thought to involve a complex interaction of genes, environmental triggers, skin barrier defects and immunologic responses.22 Raised immunoglobulin E (IgE) levels are seen in atopic eczema, but the exact role of IgE in the disease is unclear.24 Atopic eczema is present in about 80% of children where both parents are affected and in 60% if only one parent is affected.22 There has therefore been a lot of research in recent years into the genetic component attributable to atopic eczema.25-27 Loss-of-function mutations in the skin barrier protein filaggrin (FLG) is thought to contribute towards skin barrier dysfunction and are therefore a major risk for atopic eczema.122
Is there any evidence that children “grow out” of eczema in later life?

About 60% of children outgrow the disease or experience milder symptoms as they get older; however, the tendency towards dry and irritable skin is probably lifelong and the older, the tendency towards dry out” of eczema in later life?

Exacerbations.

Certain foods can contribute to environmental factors such as pets and mechanisms contributing to eczema

This is now widely considered a key physical severity of the eczema. See Table ONE.

Although atopic eczema cannot be cured, symptoms can be alleviated with good skin care and lifestyle measures. It is also important to identify the factors that exacerbate the condition and avoid them where possible. The aims of treatment are to heal skin and keep it healthy, prevent flare-ups and treat symptoms as soon as they occur and so improve quality of life.

Where are patients with atopic eczema managed?

Most patients with atopic eczema can be managed by the primary care team. Referral to a specialist is advised if the condition is severe and has not responded to appropriate therapy. About 4% of children with atopic eczema are referred to a dermatologist.

Community pharmacists

Community pharmacists are well placed to be a source of support and advice for the majority of children who are diagnosed by their GP and never see a dermatologist or specialist nurse. Community pharmacists are the healthcare professionals likely to:

- have contact with the child or parent in the early stages of the condition
- see patients every time they pick up their prescriptions or buy an over-the-counter preparation.

NICE Guidance on atopic eczema

There is a NICE clinical guideline concerning the management of atopic eczema in children from birth up to the age of 12 years. It has been developed with the aim of providing guidance on:

- diagnosis, assessment and impact
- management during and between flares
- information and education for children and their parents or carers.

NICE propose a stepped care plan approach to treatment. This is where treatment is stepped up or down according to the physical severity of the eczema. See Table TWO.

Managing Atopic Eczema

Although the scope of the NICE guideline is limited to children under the age of 12 years, the recommendations can be reasonably extrapolated to the management of older children and adults with atopic eczema, because although atopic eczema is predominantly a disorder of childhood, there is no evidence that the pathology of the condition is different in adulthood compared with childhood, and there is no suggestion that it does not respond to the same interventions.

There are currently no authoritative UK guidelines on the management of eczema in older children or adults. Hence this paper uses the NICE guideline as the basis for most recommendations for all groups, with additional information added where available.

What is meant by a “flare” of atopic eczema?

A “flare” is a worsening of eczema that results in escalation of treatment or seeking additional medical advice. NICE pragmatically defines a flare of eczema as “an increase in clinical severity (redness, oedema, or itching) of the condition”.

Why is early identification of a flare important?

Early identification and treatment of a flare can reduce the severity of the flare and allow for more conservative treatment measures (such as emollients alone and so reduce the need to use topical corticosteroids). Scratching is thought to be a major component of flare progression; it physically damages the skin and can delay healing or facilitate infection. Emollients are believed to ease itching and thus may have a role in breaking the itch-scratch cycle. Early application of topical corticosteroids may prevent the flare from worsening, and thus lead to reduced use of corticosteroids in the longer term.

Healthcare professionals should offer children with atopic eczema and their parents or carers information on how to recognise flares. They should give clear instructions on how to manage flares according to the stepped-care plan, and prescribe treatments that allow patients and/or carers to follow this plan.

Table ONE: Diagnostic criteria for atopic eczema

<table>
<thead>
<tr>
<th>Itchy skin (or parental report of scratching) in the last 12 months, plus three or more of the following:</th>
</tr>
</thead>
<tbody>
<tr>
<td>- A history of involvement of skin creases (elbows, knees, ankles, neck, or around eyes).</td>
</tr>
<tr>
<td>- A personal history of asthma or hay fever (or history of atopic disease in a first-degree relative if a child is less than 4 years of age).</td>
</tr>
<tr>
<td>- A history of a generally dry skin in the last year.</td>
</tr>
<tr>
<td>- Onset under the age of 2 years (not used if a child is less than 4 years of age).</td>
</tr>
<tr>
<td>- Visible flexural eczema (or eczema affecting cheeks or forehead and outer aspects of limbs in children less than 4 years of age).</td>
</tr>
</tbody>
</table>

Table TWO: NICE stepwise approach to management of atopic eczema

<table>
<thead>
<tr>
<th>Mild atopic eczema</th>
<th>Moderate atopic eczema</th>
<th>Severe atopic eczema</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emollients</td>
<td>Emollients</td>
<td>Emollients</td>
</tr>
<tr>
<td>Mild potency topical corticosteroids</td>
<td>Moderate potency topical corticosteroids</td>
<td>Potent topical corticosteroids</td>
</tr>
<tr>
<td>Topical calcineurin inhibitors*</td>
<td>Topical calcineurin inhibitors*</td>
<td></td>
</tr>
<tr>
<td>Bandages*</td>
<td>Bandages*</td>
<td>Phototherapy†</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Systemic therapy‡</td>
</tr>
</tbody>
</table>

* Usually only prescribed by a specialist (e.g. a GP with specialist interest in dermatology, dermatologist, or paediatrician).
† Available in secondary care only
‡ Oral corticosteroids can be prescribed short-term in primary care for severe flares. Other systemic treatments suitable for maintenance of severe eczema (e.g. methotrexate, ciclosporin or azathioprine) require referral to secondary care.
Emollients

Emollients have been used in the treatment of eczema for many decades and are almost universally recommended as first-line treatment. However there is actually very little evidence of effectiveness from controlled trials. 2,11,30

What is the role of an emollient in atopic eczema? (updated 2016)

Dry skin is an important feature of atopic eczema, but the rationale for reversing this dryness with emollients is less clear. One rationale is simply to relieve the feeling and appearance of “dryness” which many eczema sufferers choose to do. Another rationale is that emollients have soothing effect on itching and soreness and can have other useful properties; they can be exfoliative (especially when combined with products such as salicylic acid), and may have anti-inflammatory, and anti-mitotic effects especially when combined with other excipients such as laurymacrogols. 37,38

There is currently research looking into whether or not the use of emollients from birth could prevent eczema in babies with a strong family history. 12,13

How do emollients work?

To many people, the terms “emollient” and “moisturiser” are synonymous. However, technically emollients and moisturisers are different; an emollient being something that smoothes and softens the skin, usually via occlusion, and a moisturiser being something that actually adds moisture to the skin. In this document the word “emollient” is used as an inclusive term to define substances whose main actions are to:

1. Occlude the skin surface – by utilising greasy substances (e.g. white soft paraffin) to trap water in the stratum corneum, thus preventing transepidermal water loss by evaporation.

2. Encourage build up of water within the stratum corneum. 39 This involves the active movement of water from the dermis to the epidermis. Emollients that have this effect contain substances known as “humectants” (e.g. urea or glycerine). These have a low molecular weight and water-attracting properties, and as they penetrate the epidermis they draw water in from the dermis.

Some emollients contain a mixture of occlusive and humectant substances.

Which emollient? (updated 2016)

Given the lack of evidence of comparative effectiveness of the various available emollients, the correct emollient is the one that the patient will use. It is generally considered that giving patients a choice of emollient is likely to result in their choosing one that they will use frequently and regularly. 11,13,44 Adherence to emollient treatment is the key to successful therapy for atopic eczema.1

Emollients can be applied to the skin in a number of ways, including wash products (e.g. bath additives, soap substitutes and skin cleansers) or topical preparations (e.g. creams, ointments and lotions).

Often, several different emollients will be required. The severity of the condition, patient preference and site of application will often guide the choice of emollient: 41

- **Lotions** are used for the scalp and other hairy areas and for mild dryness on the face, trunk and limbs.
- **Creams** are used when more emollience is required on these latter areas.
- **Ointments** are prescribed for drier, thicker, scaler areas. They have less additives / potential allergens (so are often better tolerated) and are lipid based, so generally more effective. 119

Ointments are usually a first line option for patients presenting to secondary care (i.e. the more moderate and severe cases). However, they are not acceptable to all patients as some people find them too greasy 39 and ointments may stain clothes.

Often the best way to choose an emollient is to provide samples and ask the patient to choose the one or ones they feel suit their skin. Patients may use a thinner, less messy, lotion in the morning when getting dressed and then a thicker cream or ointment at night on retiring to bed.

NICE believe that ointments are preferable for dry skin because they are more effective than creams, but creams are preferable on red, inflamed skin because the evaporation of water-based products cools the skin. 39 This recommendation is based on clinical experience, rather than evidence from controlled trials or studies. See Table FIVE for advice on using emollients.

How should emollients be prescribed?

Emollients are probably under-used in general practice, with many patients not using an emollient at all before being prescribed a topical corticosteroid. 42 Once the preferred choice of emollient(s) is known, prescribe large quantities, frequently. 11 The amount of emollient prescribed will vary depending on the size of the person and extent and severity of the eczema 11 (see Table THREE). The amount of emollient used should far exceed other topical treatments (i.e. corticosteroids), by a factor of at least ten. 11 Where possible, pump-dispensers should be prescribed if large quantities of cream or lotion are required. 39

Why should emollients not be rubbed into the skin?

- Rubbing emollients into the skin should be discouraged because it:
  - introduces air into the emollient and reduces absorption
  - occludes or physically aggravates hair follicles, which may cause folliculitis (especially with ointments)
  - stimulates blood circulation, which generates heat and may cause itch.

Can emollients have adverse effects?

Emollients are generally thought to be safe, with limited adverse effects. However, the following have been reported:

**Sensitivity to some of the ingredients** (more common in children than adults) - The most common adverse effect seen with emollients is a rash caused by sensitivity of the skin to one or more of the ingredients in the product. 11 The skin shows an immediate and dose-dependent inflamed response. 11 The ingredients that have been reported to cause sensitisation reactions in skin are listed in Table FOUR. If a skin reaction occurs, stop the product and use a different emollient. If the person has had previous skin reactions to emollients:

- test a small quantity first (e.g. on the skin of the inner arm) before widespread application, 11
- the chance of a further reaction is reduced by prescribing an ointment (these do not require preservatives and generally have fewer excipients). 11

Folliculitis

Use of very greasy ointments can block the hair follicles, which can lead to irritation and inflammation. This can usually be avoided by stroking, rather than rubbing, the emollient into the skin following the directional lie of the hair and/or using a lighter, less occlusive product. Occasionally blockage of the hair follicle may lead to painful pustules and infection, causing folliculitis. Antibiotics may be needed. However, stopping the product is often sufficient to resolve the problem.

Slip hazard (bath additives)

Bath emollients can pose a slip hazard. 11

- Fire Hazard with paraffin-based emollients 41,44

Emulsifying ointment or Liquid Paraffin and White Soft Paraffin in contact with dressings and clothing are easily ignited by a naked flame. The risk is greater when these preparations are applied to large areas of the body, and clothing or dressings become soaked with the ointment. Patients should be told to keep away from fire or flames, and not to smoke when using these preparations.

---

Table FIVE: Advice on using emollients

<table>
<thead>
<tr>
<th>Area affected</th>
<th>Creams and ointments (grams)</th>
<th>Lotions (ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Face</td>
<td>15-30</td>
<td>100</td>
</tr>
<tr>
<td>Both hands</td>
<td>25-50</td>
<td>200</td>
</tr>
<tr>
<td>Scalp</td>
<td>50-100</td>
<td>200</td>
</tr>
<tr>
<td>Both arms</td>
<td>100-200</td>
<td>200</td>
</tr>
<tr>
<td>Trunk</td>
<td>400</td>
<td>500</td>
</tr>
<tr>
<td>Groin and genitalia</td>
<td>15-25</td>
<td>100</td>
</tr>
</tbody>
</table>

* For children, about half these amounts are suitable

---

Table THREE: Quantities of emollients that should be prescribed for adults* with eczema, per week

<table>
<thead>
<tr>
<th>Area affected</th>
<th>Creams and ointments</th>
<th>Lotions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Face</td>
<td>15-30</td>
<td>100</td>
</tr>
<tr>
<td>Both hands</td>
<td>25-50</td>
<td>200</td>
</tr>
<tr>
<td>Scalp</td>
<td>50-100</td>
<td>200</td>
</tr>
<tr>
<td>Both arms</td>
<td>100-200</td>
<td>200</td>
</tr>
<tr>
<td>Trunk</td>
<td>400</td>
<td>500</td>
</tr>
<tr>
<td>Groin and genitalia</td>
<td>15-25</td>
<td>100</td>
</tr>
</tbody>
</table>

* For children, about half these amounts are suitable.
apply with having topical emollients
emollient to a large skin surface area, that it is an easier way of applying an
prescribed bath emollients. In Northern Ireland, we spend over £620,000
people with atopic eczema are commonly
advising to apply emollient
additive? 
substitutes are also available.
be used as soap substitutes for hand
organic matter and enhance the lipid coating
over the body (using hands or a wash cloth)
These are used like soap, being applied
What are “soap substitutes”? 
These are used like soap, being applied
emollient used (products with higher water content lose effectiveness faster).
The effects of emollients are short-lived, and will depend on several factors such as the dryness of the skin and the type of
emollient used (products with higher water content lose effectiveness faster). Use emollients liberally and frequently, even
when the skin appears improved or is clear.
• For very dry skin, application of an emollient every 2-3 hours should be considered normal.
• The amount and frequency of emollient used will need to increase at the first sign of any worsening of the condition.
• Even if other treatments such as topical corticosteroids are being used, regular use of emollients should continue.
• To facilitate frequent application, the person should consider keeping packs of emollients at work or school.
Applying emollients:
• Healthcare professionals should demonstrate to patients or their carers how to apply emollients.
• Apply by smoothing them into the skin in the direction of hair growth (rather than rubbing them in).
Washing:
• Avoid using soaps, detergents and bubble bath. Instead use a suitable soap substitute, for example an ointment dissolved in
hot water or lotion in warm water.
• Dry the skin gently after washing and apply the emollient straight away while the skin is still moist.
• Use of emolient bath additives and shower gels can be considered in people with extensive areas of dry skin. However, their
use should supplement, not replace, emollients designed to be left on the skin.
• Bathing hydrates and cleanses the skin and emollient based soap substitutes moisturise the skin. Bathing is therefore usually
recommended once a day.119 (updated 2016)
Emollients should not be shared with other people.
Wait 10-15 minutes after application of an emollient before applying a topical corticosteroid.

Table FOUR: Potential sensitising ingredients found in emollients 39,41

<table>
<thead>
<tr>
<th>Ingredient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beeswax</td>
</tr>
<tr>
<td>Benzyl alcohol</td>
</tr>
<tr>
<td>Butylated hydroxytoluenes</td>
</tr>
<tr>
<td>Cetostearyl alcohol</td>
</tr>
<tr>
<td>EDTA</td>
</tr>
<tr>
<td>Fragrances</td>
</tr>
<tr>
<td>Hydroxybenzoates</td>
</tr>
<tr>
<td>Imidazure</td>
</tr>
<tr>
<td>Isopropyl palmitate</td>
</tr>
<tr>
<td>N-(3-Chlorallyl) hexamine chloride</td>
</tr>
<tr>
<td>Polysorbates</td>
</tr>
<tr>
<td>Propylene glycol</td>
</tr>
<tr>
<td>Sodium metabisulphite</td>
</tr>
<tr>
<td>Sorbic acid</td>
</tr>
<tr>
<td>Wool fat and related substances (including lanolin)*</td>
</tr>
</tbody>
</table>

* Although lanolin has often been reported in the literature as a potent sensitisier; newer more highly refined (hypo-allergenic) types of lanolin rarely cause adverse reactions. 43

What is “complete emollient therapy”? 
“Complete emollient therapy” (CET) involves the use of a topical emollient cream or ointment, emollient bath oil and emollient soap substitute, backed up with education on how to use them. (Soaps and detergents, including so-called “moisturising soaps” and bubble baths, must be avoided at all times). CET is based on the premise that the patient’s skin should be protected from soap and detergents as far as possible and treated with emollients as frequently as possible.

Is the use of emollients steroid-sparing? 
Effective use of emollients can have a steroid-sparing effect; that is to say the beneficial effects of the steroid treatment are achieved at a lower dose than if the steroid product had been used alone. 48, 49, 50 This may be a useful point to make to patients as many of them are concerned about the long-term effects of using steroids.

Prescribing point: Aqueous cream
Aqueous cream was originally devised as a soap substitute, not a topical emollient. When applied directly to the skin as an emollient, aqueous cream causes significantly more stinging than other emollients. 48 It has also been shown to increase transepidermal water loss. 119 Thus, use of aqueous cream as a topical emollient should be avoided. 11, 44 As a soap substitute it is generally well tolerated.

Prescribing point: BRAND prescribing of multi-ingredient creams and ointments
It is considered inappropriate to prescribe products with multi-ingredients generically. Creams, ointments, bath oils, lotions etc which contain many active ingredients should be prescribed by brand name. 47

Table FIVE: Advice on using emollients 11, 41

The effects of emollients are short-lived, and will depend on several factors such as the dryness of the skin and the type of emollient used (products with higher water content lose effectiveness faster). Use emollients liberally and frequently, even when the skin appears improved or is clear.
• For very dry skin, application of an emollient every 2-3 hours should be considered normal.
• The amount and frequency of emollient used will need to increase at the first sign of any worsening of the condition.
• Even if other treatments such as topical corticosteroids are being used, regular use of emollients should continue.
• To facilitate frequent application, the person should consider keeping packs of emollients at work or school.
Applying emollients:
• Healthcare professionals should demonstrate to patients or their carers how to apply emollients.
• Apply by smoothing them into the skin in the direction of hair growth (rather than rubbing them in).
Washing:
• Avoid using soaps, detergents and bubble bath. Instead use a suitable soap substitute, for example an ointment dissolved in hot water or lotion in warm water.
• Dry the skin gently after washing and apply the emollient straight away while the skin is still moist.
• Use of emolient bath additives and shower gels can be considered in people with extensive areas of dry skin. However, their use should supplement, not replace, emollients designed to be left on the skin.
• Bathing hydrates and cleanses the skin and emollient based soap substitutes moisturise the skin. Bathing is therefore usually recommended once a day. 119 (updated 2016)
Emollients should not be shared with other people.
Topical corticosteroids

Many patients with atopic eczema need to use topical corticosteroid preparations intermittently when the condition flares and a few patients need to use them long-term. Topical corticosteroids are the first-line treatment for flare-ups of atopic eczema. They do not cure the condition but they will control it via anti-inflammatory and immunosuppressive effects. Topical corticosteroids reduce inflammation and relieve itching, although the mechanism by which they do this is largely unclear.

Evidence of the effectiveness of topical steroids in atopic eczema.

Topical corticosteroids have been a vital component of treatment for atopic eczema since the development of hydrocortisone in 1952. The development of the early topical corticosteroids preceded the use of high-quality RCTs to determine clinical effectiveness. As a result, evidence from controlled trials for effectiveness of this group of drugs is limited. Clinical experience has shown that topical steroids improve atopic eczema over a two to four week period. Initial improvement should be seen within 3-7 days of starting topical steroids.

Relative potency of topical steroids

The BNF categorises topical corticosteroids for the skin as "mild", "moderately potent" "potent" or "very potent". Table SIX shows the potency of various corticosteroid preparations. The potency of each corticosteroid is measured by its ability to cause vasoconstriction, rather than its clinical effectiveness. "Very potent" topical corticosteroids are up to 600 times as potent as mild topical corticosteroids. Potency is also affected by the formulation and other ingredients, for example, propylene glycol, urea or salicylic acid may enhance absorption of steroids. The salt of the steroid may also affect potency, e.g. hydrocortisone sodium phosphate is a mild steroid, while hydrocortisone butyrate is classified as potent

How do I decide which topical corticosteroid to prescribe?

The choice of topical corticosteroid is based on potency of the preparation and the site and severity of the condition. Use:

- Mild potency for mild atopic eczema
- Moderate potency for moderate atopic eczema
- Potent for severe atopic eczema
- Mild potency for the face and neck, except for short-term (3-5 days) use of moderate potency for severe flares
- Moderate or potent preparations for short periods only (7-14 days) for flares in vulnerable sites such as axillae or groin.

Do not use very potent preparations without specialist dermatological advice. NICE recommends that where more than one alternative topical corticosteroid is considered clinically appropriate within a potency class, the drug with the lowest acquisition cost should be prescribed, taking into account pack size and frequency of application.

Formulation aspects of topical corticosteroid preparations

It is important to consider the base in which the corticosteroid is supplied. Corticosteroid creams are more suitable for skin which is:

- moist or weeping (ointments are difficult to apply to wet areas)
- infected so that the infected area is not occluded.
- visible, such as the face and hands

Corticosteroid ointments are more suitable for:

- dry lichenified or scaly lesions
- when a more occlusive effect is required

Corticosteroid lotions are more suitable for:

- minimal application to a large or hair-bearing area
- treatment of exudative lesions.

OTC sale of topical corticosteroids

Creams and ointments containing hydrocortisone 1% (alone or with other ingredients) can be sold to the public for the treatment of allergic contact dermatitis, irritant dermatitis, insect bite reactions and mild to moderate eczema, to be applied sparingly over the affected area 1-2 times a day for a maximum of one week.

Clobetasone butyrate 0.05% cream may be sold for the short-term treatment and control of small patches of atopic eczema in adults and children over 12 years of age provided the pack does not contain more than 15 grams.

Prescribing point: Hydrocortisone cream — note strength (updated 2016)

When prescribing hydrocortisone, some GP clinical systems automatically default to the 0.1% strength. Ensure that the intended strength of hydrocortisone is selected.

What adverse effects are associated with the use of topical steroids?

The adverse effects of topical corticosteroids are well recognised but often exaggerated. Side-effects generally only occur following the incorrect use of potent steroids over a long period of time. The following factors can influence the likelihood of adverse effects:

- Site of treatment - absorption is greatest from intertriginous areas.
- Skin thickness - absorption is greatest where the skin is thin
- Skin condition - greater absorption occurs when the skin is damaged.
- Patient age - children, especially infants, are particularly susceptible to side-effects.
- Potency of preparation - mild and moderately potent topical corticosteroids are associated with few side-effects but care is required in the use of potent and very potent corticosteroids.

- Duration of treatment
- Local side-effects include:
  - Transient burning or stinging is common and may necessitate changing the product.
  - Spread and worsening of untreated infection.
  - The skin can become thin and easily bruised. It is particularly common in the skin of the elbow creases and behind the knees. Studies in healthy volunteers showed skin thinning at 6 weeks, which completely reversed after treatment was stopped but the original skin structure may never return.
  - Irreversible striae atrophicae - prolonged or excessive use of potent steroids causes the dermis to lose its elasticity and stretch marks (striae) to appear, which are permanent.
  - Telangiectasia - especially on the cheeks.
  - Steroid-induced dermatitis - contact sensitivity can develop not only to preservatives within steroid preparations, but also to the steroid molecule itself.
  - Perioral dermatitis.
  - Acne.
  - Mild depigmentation - may be reversible.
  - Hypertrichosis.
  - Rebound flare – if topical steroids are stopped abruptly.
  - Cataracts and glaucoma – following application of topical corticosteroids on the eyelid region.

When topical corticosteroids are used correctly, systemic adverse effects are very rare but include adrenal suppression that can result in symptoms of Cushings syndrome and growth retardation in children. However, a study of children using topical corticosteroids for atopic eczema for a median of 6.9 years found evidence of HPA axis suppression only in those using potent or very potent topical corticosteroids or those who had received corticosteroids from other routes (inhaled, intranasal, or oral).

What can be done to minimise the risk of adverse effects?

In order to minimise the side-effects of a topical corticosteroid, it is important to:

- Apply it thinly to affected areas only
- Apply it no more frequently than twice daily
- Use the least potent formulation which is fully effective.

Check for signs of adverse effects at review, such as areas of thin skin or striae in children who are using large amounts of topical corticosteroid, monitor height.

Prescribing point: Monitor large quantities of topical steroids

Patients persistently using large quantities of topical corticosteroids should be monitored. There is no definition of what is meant by “large quantities”, but an adult using more than 100 grams of potent corticosteroid per month, for several months, should trigger a review.
With the exception of hydrocortisone 0.1% - 2.5%, topical corticosteroid preparations should be prescribed by BRAND name. This is to avoid confusion between products, and because potency of topical corticosteroid preparations is a result of the formulation as well as the corticosteroid. (updated 2016)

### Table SIX: Topical Corticosteroid Preparation Potencies

<table>
<thead>
<tr>
<th>Potency</th>
<th>Examples – steroid alone</th>
<th>Steroid plus antimicrobial</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MILD</strong></td>
<td>• Hydrocortisone 0.1% - 2.5% (non-proprietary) NIF</td>
<td>• Canestan HC® (hydrocortisone, clotrimazole) NIF</td>
</tr>
<tr>
<td></td>
<td>• Synalar 1 in 10 dilution® (fluocinolone 0.0025%)</td>
<td>• Daktaforc® (hydrocortisone, miconazole) NIF</td>
</tr>
<tr>
<td></td>
<td>• Haelian® (fluoroxycortide)</td>
<td>• Econaforc® (hydrocortisone, econazole)</td>
</tr>
<tr>
<td></td>
<td>• Modrasone® (alclometasone)</td>
<td>• Fucidin H® (hydrocortisone, fusidic acid) NIF</td>
</tr>
<tr>
<td></td>
<td>• Synalar 1 in 4 dilution® (fluocinolone) NIF</td>
<td>• Nystaform-HC® (hydrocortisone, nystatin, chlorhexidine)</td>
</tr>
<tr>
<td></td>
<td>• Ultralium Plain® (fluocortalone)</td>
<td>• Timodine® (hydrocortisone, nystatin, benzalkonium chloride)</td>
</tr>
<tr>
<td><strong>MODERATE</strong></td>
<td>• Betnovate-RD® (betamethasone 0.025%) NIF</td>
<td>• Trimmovate® (clobetasone, oxytetracycline, nystatin) NIF</td>
</tr>
<tr>
<td></td>
<td>• Eumovate (clobetasone) NIF (1st choice)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Haelian® (fluoroxycortide)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Modrasone® (alclometasone)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Synalar 1 in 4 dilution® (fluocinolone) NIF</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Ultralium Plain® (fluocortalone)</td>
<td></td>
</tr>
<tr>
<td><strong>POTENT</strong></td>
<td>• Betacap®, Betramousse®, Betnovate® NIF, Diprosone® (betamethasone 0.1%)</td>
<td>• Aureocort® (triamcinolone, chlortetracycline)</td>
</tr>
<tr>
<td></td>
<td>• Cutivate® (fluicasone)</td>
<td>• Fucibet® (betamethasone, fusidic acid) NIF</td>
</tr>
<tr>
<td></td>
<td>• Elocon® (mometasone) NIF</td>
<td>• Lotriderm® (betametasone, clotrimazole)</td>
</tr>
<tr>
<td></td>
<td>• Locoid®, Locoid Crelo® (hydrocortisone butyrate 0.1%)</td>
<td>• Synalar C® (fluocinolone, clioquinol)</td>
</tr>
<tr>
<td></td>
<td>• Metosyn® (fluocinonide)</td>
<td>• Synalar N (fluocinolone, neomycin)</td>
</tr>
<tr>
<td></td>
<td>• Nerisone® (difluertolone)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Synalar® (fluocortalone)</td>
<td></td>
</tr>
<tr>
<td><strong>VERY POTENT</strong></td>
<td>• Clarelux®, Dermovate® NIF, Etrivex® (Clobetasol 0.05%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Nerisone Forte® (diflucortalone)</td>
<td></td>
</tr>
</tbody>
</table>

* NIF Northern Ireland Formulary choice [http://niformulary.hscni.net](http://niformulary.hscni.net)

### Dispensing note: Topical corticosteroids

NICE guidance indicates that healthcare professionals who dispense topical corticosteroids should apply labels to the container (for example, the tube), not the outer packaging. The label should also state the potency class of the preparation.

Concern about the safety of topical steroids should not result in the patient being undertreated. The aim is to control the condition as well as possible; inadequate treatment will perpetuate the condition. Healthcare professionals should discuss the benefits and harms of treatment with topical corticosteroids with patients or carers, emphasising that the benefits outweigh possible harms when they are used correctly.

**What is “steroid-phobia”?**

Many patients are reticent about using topical steroids because of the fear of side-effects. Steroid phobia is a real phenomenon with some people being so frightened that they will not use steroids, even when they have been prescribed. Furthermore, confusion about potency is common. Surveys and questionnaires of dermatology outpatients with atopic eczema have shown:

- 72% of patients (or their carers) are worried about using topical steroids.
- 24% admitted to not having used prescribed topical steroids because of worries about side-effects.
- 9.5% of patients were worried about systemic absorption of the steroid.
- 42% of patients who used potent topical corticosteroids perceived it to be moderate or weak. This could lead to inappropriate use and increased risk of side-effects.
- 44% incorrectly graded hydrocortisone as moderate or potent and may have used it inadequately because of worries about potential side-effects.

**Avoiding steroid phobia / communicating to patients** (updated 2016)

Framing the very small risk of side effects in context with plenty of reassurance about the safety and benefit of appropriate treatment can relieve steroid phobia and prevent it from occurring.

**Topical corticosteroids – apply once or twice a day?**

Once-daily application of topical corticosteroids is widely endorsed and should be used as a first-step in all patients with atopic eczema. If necessary, use can be increased to twice daily to bring the condition under control before stepping down again to once-daily.

**Topical corticosteroids – duration of treatment?** (updated 2016)

Use mild potency for the face and neck, except for short-term (3 to 5 days) use of moderate potency for severe flares. Use moderate or potent preparations for short periods only (7 to 14 days) for flares in vulnerable sites such as axillae and groin. Exclude secondary bacterial or viral infection if a mild or moderately potent topical corticosteroid has not controlled the atopic eczema within 7-14 days.

**Where should topical corticosteroids be applied?**

Topical corticosteroids should only be applied to areas of active atopic eczema (or eczema that has been active within the past 48 hours); this may include areas of broken skin.

**If a topical steroid and an emollient are to be applied, which should be applied first?**

Advise the person to use their emollient first, then wait 10-15 minutes before applying the topical corticosteroid (after the emollient has been absorbed.

### Table SEVEN: Suitable quantities of steroid cream/ointment to be prescribed for specific areas

<table>
<thead>
<tr>
<th>Area</th>
<th>Suitable quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Face and neck</td>
<td>15 to 30 grams</td>
</tr>
<tr>
<td>Both hands</td>
<td>15 to 30 grams</td>
</tr>
<tr>
<td>Scalp</td>
<td>15 to 30 grams</td>
</tr>
<tr>
<td>Both arms</td>
<td>30 to 60 grams</td>
</tr>
<tr>
<td>Both legs</td>
<td>100 grams</td>
</tr>
<tr>
<td>Trunk</td>
<td>100 grams</td>
</tr>
<tr>
<td>Groins and genitalia</td>
<td>15 to 30 grams</td>
</tr>
</tbody>
</table>
Can topical corticosteroids be used as “maintenance” treatment in atopic eczema? (updated 2016)

Intermittent treatment with a moderate or potent topical corticosteroid is as effective as continuous treatment with a mild corticosteroid. In practice, twice weekly treatment with a moderate steroid is usually sufficient and this would be the standard maintenance therapy in local paediatric dermatology units. Some patients will require twice weekly potent corticosteroids. Healthcare professionals should consider treating problem areas of atopic eczema with topical corticosteroids for two consecutive days per week (so-called “weekend therapy”) to prevent flares, instead of treating flares as they arise, in people with frequent flares (two or three per month), once the eczema has been controlled. A different topical corticosteroid of the same potency should be considered as an alternative to stepping up treatment if tachyphylaxis to a topical corticosteroid is suspected. Patients are often advised to apply topical corticosteroids “sparingly” or “thinly”. This rightly recognises the potential for side-effects that have been associated with inappropriate, prolonged and/or excessive use of topical corticosteroids, especially the more potent agents. However, the advice to apply “sparingly” or “thinly” carries with it messages of economy, caution and even danger. Certainly, there is good evidence that patients interpret this warning in a negative way, giving rise to steroid phobia, with accompanying poor adherence to treatment. The “finger-tip unit”, first introduced in the early 1990s, is a simple tool to help health professionals and patients obtain a better understanding of the amount of topical products, they should use on different parts of the body. One “finger unit” (FTU) is the quantity of cream or ointment required to go from the tip of the patient’s index finger to the first joint as it is squeezed out of the tube and is equivalent to 0.5 grams of cream or ointment. Topical steroids should be applied in the amounts shown in Table EIGHT.

### Topical calcineurin inhibitors

Two topical calcineurin inhibitors are available to treat atopic eczema: tacrolimus (Protopic® ointment) and pimecrolimus (Elidel® cream).

#### How do tacrolimus and pimecrolimus work?

Tacrolimus and pimecrolimus are topical immunomodulators classified as calcineurin inhibitors. Although they also act on other cells playing a role in atopic eczema (mast cells, Langerhan’s cells, B-lymphocytes), their action on T-lymphocytes seems to be the most important. Although tacrolimus and pimecrolimus have similar mechanisms of action, they have different licensed indications (see later).

#### What is the place of topical calcineurin inhibitors in the management of atopic eczema?

In its appraisal of these agents, NICE recommends that, within their licensed indications:

- Topical tacrolimus is an option for the second-line treatment of moderate to severe atopic eczema in adults and children aged 2 years and older.
- Topical pimecrolimus is an option for the second-line treatment of moderate atopic eczema on the face and neck in children aged 2–16 years. In either case, the atopic eczema will not have been controlled by topical corticosteroids or there is a serious risk of important adverse effects from further topical corticosteroid use, particularly irreversible skin atrophy.

Treatment with tacrolimus or pimecrolimus should be initiated only by physicians (including general practitioners) with a special interest and experience in dermatology, and only after careful discussion with the patient about the potential risks and benefits of all appropriate second-line treatment options. See Table TEN.

#### How much tacrolimus and pimecrolimus are prescribed in primary care in Northern Ireland?

See chart of prescribing data.

#### Efficacy of tacrolimus and pimecrolimus

Tacrolimus and pimecrolimus have been shown to be effective in the treatment of atopic eczema. Trials have shown a rapid reduction of symptoms within a few days of therapy; they are effective in both the short- and long-term, and in adults and children. When compared to topical steroids:

- Tacrolimus is more effective than mild topical steroids and equally effective to moderately potent topical steroids. Pimecrolimus has been found to be equivalent in efficacy to mild topical steroids and less effective than moderately potent topical corticosteroids. Although less effective than potent topical corticosteroids, pimecrolimus has value in the long-term maintenance and steroid-sparing effect in atopic eczema. This is particularly true if pimecrolimus is used early in the disease course. In moderate to severe atopic eczema, application of pimecrolimus cream regularly for 6 months resulted in significantly fewer flares of eczema and significant reduction of the use of topical corticosteroids.

#### What are the advantages of tacrolimus and pimecrolimus?

<table>
<thead>
<tr>
<th>Body site</th>
<th>Adults (3-6 mths)</th>
<th>Child (1-2 years)</th>
<th>Child (3-5 years)</th>
<th>Child (6-10 years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Face and neck</td>
<td>2.5</td>
<td>1</td>
<td>1.5</td>
<td>1.5</td>
</tr>
<tr>
<td>Arm and hand</td>
<td>4</td>
<td>1</td>
<td>1.5</td>
<td>2</td>
</tr>
<tr>
<td>Leg and foot</td>
<td>8</td>
<td>1.5</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Trunk (front)</td>
<td>7</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Trunk (back) &amp; buttocks</td>
<td>7</td>
<td>1.5</td>
<td>2</td>
<td>3.5</td>
</tr>
</tbody>
</table>

Note: Some topical steroid creams are available in pump dispensers, in which case one action of the pump is equivalent to two FTUs.

---

**Table EIGHT: Fingertip units (FTUs) required**

<table>
<thead>
<tr>
<th>Body site</th>
<th>Adults (3-6 mths)</th>
<th>Child (1-2 years)</th>
<th>Child (3-5 years)</th>
<th>Child (6-10 years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Face and neck</td>
<td>2.5</td>
<td>1</td>
<td>1.5</td>
<td>1.5</td>
</tr>
<tr>
<td>Arm and hand</td>
<td>4</td>
<td>1</td>
<td>1.5</td>
<td>2</td>
</tr>
<tr>
<td>Leg and foot</td>
<td>8</td>
<td>1.5</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Trunk (front)</td>
<td>7</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Trunk (back) &amp; buttocks</td>
<td>7</td>
<td>1.5</td>
<td>2</td>
<td>3.5</td>
</tr>
</tbody>
</table>

Note: Some topical steroid creams are available in pump dispensers, in which case one action of the pump is equivalent to two FTUs.
Unlike topical corticosteroids, tacrolimus and pimecrolimus do NOT interfere with collagen synthesis or induce skin atrophy. This could be a major advantage for long-term use and for use on the face and neck. Pimecrolimus is minimally absorbed even when the drug is applied to large areas of inflamed skin.

How should tacrolimus or pimecrolimus be used?
See Table NINE.

Adverse effects of tacrolimus

Application site reactions:
In studies, approximately 50% of patients applying topical tacrolimus experienced some type of skin irritation at the site of application. A burning sensation and pruritus were very common, usually mild to moderate in severity and tended to resolve within one week of starting treatment. Patients/carers should also be told to avoid application after bathing as this will enhance the discomfort.

Erythema was also a common adverse skin reaction. Sensations of warmth, pain, paraesthesia and rash at the site of application are also commonly observed. Patients may be at an increased risk of folliculitis, acne and herpes viral infections.

Systemic reactions:
In trials, the most common systemic adverse events were:
- flu-like symptoms
- headache
- alcohol intolerance (facial flushing or skin irritation after consumption of alcohol).

As with topical corticosteroids, tacrolimus treatment is suppressive and discontinuation of treatment frequently leads to recurrence of eczema.

Adverse effects of pimecrolimus

Local side effects include a burning sensation, pruritus, erythema, skin infections (including folliculitis, impetigo, herpes simplex and zoster, and molluscum contagiosum), papilloma (rarely) and local reactions such as pain, paraesthesia, peeling, dryness, oedema and worsening eczema. Skin reactions to pimecrolimus are usually mild and transient, however, if the application site reaction is severe, the risk/benefit of treatment should be re-evaluated.

Malignancies (updated 2016)
The MHRA issued a warning in 2012 that topical tacrolimus may be associated with a possible risk of malignancy: cases of lymphomas and skin cancers have been reported. In addition, findings from epidemiological studies have suggested a possible increased risk of cutaneous T-cell lymphoma in patients treated with topical calcineurin inhibitors, including tacrolimus ointment.

A systematic review and meta-analysis has since reviewed the risk of lymphoma in patients with atopic eczema. The review found a slightly increased risk of lymphoma in patients with atopic eczema. Severity of atopic eczema appeared to be a significant risk factor; the role of topical calcineurin inhibitors was unlikely to be significant. The safety profiles of calcineurin inhibitors are overall reassuring to date, with no causal link with cancer shown. However, longer term data is needed.

Until further data is available the following cautions apply:
- do not prescribe Protopic® to patients younger than 2 years,
- use of Protopic® in children aged 2 to 16 years is restricted to the lower strength 0.03% ointment only.
- do not apply Protopic® to lesions that are considered to be potentially malignant or pre-malignant,
- do not use Protopic® in patients with congenital or acquired immunodeficiencies, or in patients on therapy that causes immunosuppression.

Can tacrolimus or pimecrolimus be used in infected eczema?
The safety and efficacy of tacrolimus or pimecrolimus has not been evaluated in clinically infected atopic eczema. Hence, before beginning treatment with tacrolimus or pimecrolimus, clinical infections at treatment sites should be cleared.
Systemic therapy of atopic eczema

In a subgroup of patients with moderate to severe atopic eczema, the disease cannot be sufficiently controlled with conventional topical treatments and systemic treatments become necessary.

Ciclosporin
Ciclosporin is an immunosuppressant prodrug that acts by inhibiting T-cell function. The role of ciclosporin in severe, recalcitrant atopic eczema is well established. In patients in whom atopic eczema cannot be controlled by standard topical therapies, ciclosporin significantly decreases symptom scores, disease extent, pruritus and sleep deprivation, and has been shown to improve quality of life.

Adverse effects of ciclosporin
The most common adverse effects of ciclosporin are hypertension, renal dysfunction, headache, hypotension, gingival hyperplasia and paraesthesia. Ciclosporin requires careful monitoring.

Azathioprine
Azathioprine is a long-acting systemic immunosuppressive agent affecting purine nucleotide synthesis and metabolism.

Methotrexate (updated 2016)
Methotrexate has anti-inflammatory effects and reduces allergen specific T-cell activity. It is increasingly used in the management of atopic eczema. Evidence for the use of methotrexate in eczema is limited, but trials in the UK are underway. One RCT suggests that methotrexate and azathioprine are equally effective in treating eczema in the short term, but larger adequately powered studies with longer follow-up are needed.

Alitretinoin capsules (Tocido®)
Alitretinoin is a derivative of retinoic acid that binds to and activates intracellular retinoid receptors. These receptors regulate cellular differentiation and proliferation.

How big a problem is hand eczema?
Hand eczema affects about 10% of the general population and up to 30% of high risk occupational groups, such as healthcare workers and workers in manufacturing industries. Approximately 7% of people with hand eczema are thought to have a severe, chronic form.

How is oral alitretinoin used?
The recommended dosage is 30 milligrams once daily for 12-24 weeks. The dosage can be reduced to 10 milligrams once daily if there are unacceptable adverse effects. The SmPC specifies that if a person still has severe disease after the first 12 weeks, stopping the treatment should be considered. In the event of relapse, further treatment courses may be of benefit. Alitretinoin should be prescribed only by, or under the supervision of, a consultant dermatologist.

What adverse effects have been associated with alitretinoin?
The most frequent adverse effects seen with alitretinoin include headache, dry mouth, anemia, flushing and erythema. Increases in cholesterol and triglyceride levels have also been observed. Adverse effects are generally dose related and reversible.

Alitretinoin is teratogenic and is contraindicated in women of childbearing potential unless all of the conditions of the Pregnancy Prevention Programme (as outlined in the SmPC) are met.

Prescribing points: Red / Amber issues
- In Northern Ireland, ciclosporin and azathioprine are on the amber list of specialist medicines and as such are initiated on the recommendation of a specialist within a shared care arrangement.
- Alitretinoin is a red list agent and should only be prescribed in the hospital setting by a specialist.
- See www.jnsm.hscni.net

Antihistamines
The most common and least tolerated symptom of atopic eczema is itching. It is usually worse at night and frequently disrupts sleep. Patients with atopic eczema have a reduced threshold for pruritus and its control allows an important improvement in quality of life for both patients and caregivers.

For decades, elevated histamine levels measured in the skin of patients with atopic eczema were considered responsible for inflammation and itching. This led to the concept that antihistamines would be of potential benefit in the management of pruritus. However, a dominant feature, NICE recommend that clinical experience still supports the use of antihistamines in some situations, although this should not be routine. To assess whether treatment is of benefit, it is worth considering a short trial on an individual basis:

- a 1 to 2 week trial of a sedating antihistamine during an acute flare if sleep disturbance has a significant impact.
- A 1-month trial of a non-sedating antihistamine for patients with severe atopic eczema or patients with mild or moderate disease where there is severe itching or urticaria. Treatment can be continued, if successful, while symptoms persist, and reviewed every 3 months.

Prescribe cetirizine, fexofenadine (updated 2016) or loratadine once daily if a non-sedating antihistamine is required (both are available generically).

Chlorphenamine is recommended if a sedating antihistamine is required.

Oral corticosteroids
Oral corticosteroids are rarely used except for an acute flare with body surface area involvement over 40%.

What issues should be considered before prescribing an oral corticosteroid in atopic eczema?
Prescribe only a short course of an oral corticosteroid: 30 milligrams of prednisolone taken each morning for one week should be sufficient. Consider referring a patient if:

- The patient is aged less than 16 years.
- More than very occasional use of oral corticosteroids is needed (e.g. more than one course in a year).
- The patient has a reduced tolerance to steroids.
- The patient has a history of steroid induced diabetes.
- The patient has severe, recalcitrant atopic eczema.
- Moderate to severe atopic eczema.
- There is an unacceptable adverse effect.

Phototherapy
Phototherapy can be considered for the treatment of severe atopic eczema when other management options have failed or are inappropriate and there is a significant negative impact on quality of life.

Dry bandages and medicated dressings including wet wrap therapy
Localised medicated dressings or dry bandages can be used with emollients as a treatment for areas of chronic lichenified atopic eczema in children. They can also be used for short-term treatment of flares (7-14 days). Such treatment should not be used as first-line treatment for atopic eczema and should only be initiated by a healthcare professional trained in their use.
Wet dressings are useful in children with severe widespread eczema. This is essentially an inpatient procedure but can be used for short periods at home. A water-based emollient is applied all over; a corticosteroid cream is applied to the areas of active eczema. The creams are covered with a double layer of wrapping, the innermost of which is wetted with tepid water. The wet wraps are usually left on overnight.

Complementary therapies

The use of Chinese herbal medicine in the management of atopic eczema became popular a few years ago, but evidence of benefit is mixed. Patients should be informed that the effectiveness and safety of therapies such as homeopathic, herbal medicine, massage and food supplements for the management of atopic eczema have not yet been adequately assessed in clinical studies. In addition, they should be cautious with the use of herbal medicines and be wary of any product that is not labelled in English or does not come with information about safe usage.

Topical corticosteroids are deliberately added to some herbal products intended for use in atopic eczema.

Liver toxicity has been associated with the use of some Chinese herbal medicines intended to treat eczema. Patients should inform their healthcare professionals if they are using or intend to use complementary therapies.

Infection & the role of antimicrobials (updated 2016)

Infection is a common complication of atopic eczema. Bacterial infection (commonly with Staphylococcus aureus and occasionally with Streptococcus pyogenes) can exacerbate eczema and requires treatment with topical or systemic antibacterial drugs along with topical corticosteroids. People with atopic eczema (or their carers) should be offered information on how to recognise the symptoms and signs of bacterial infection (weeping, pustules, crusts, atopic eczema failing to respond to therapy, rapidly worsening atopic eczema, fever and malaise). Healthcare professionals should provide clear information on how to access appropriate treatment if infection is suspected.

Topical antimicrobials

Topical preparations for infection are available, including fusidic acid (Fucicort® cream or ointment) and mupirocin (Bactroban® cream or ointment). Some preparations are also combined with a stool, e.g., fusidic acid and betametasone (Fucibet® cream). However, despite their widespread use, there is no evidence that topical antimicrobials are of any benefit. Given the risk of development of bacterial resistance, they should only be considered for use on single small lesions for short periods of time (maximum two weeks). Mupirocin should be reserved for MRSA infection. Where necessary, topical fusidic acid (cream or ointment) applied three times daily for 5 days is suggested.

Systemic antimicrobials

Systemic antibiotics that are active against Staphylococcus aureus and streptococcus should be used to treat widespread bacterial infections of atopic eczema. For adults, guidelines suggest flucloxacillin orally 500 milligrams four times daily for 7 days. Erythromycin 250mg four times a day for seven days or clarithromycin orally 250-500 milligrams twice daily for 7 days are alternatives (for corresponding doses for children see BNF).

How can further episodes of infection be prevented?

Topical preparations should be discarded after the infection has cleared, as pathogens can contaminate them and survive in product packaging; this applies particularly to creams packaged in tubs and tubes, although is probably less with pump-dispensers. ‘Bleach baths’ (where a mild bleach and water solution is used to decrease bacteria on the skin) now forms part of the standard management of recurrent infection in eczema in local paediatric dermatology units.

Infection with herpes simplex and eczema herpeticum

Healthcare professionals should consider infection with herpes simplex (cold sore) virus if a child’s infected atopic eczema fails to respond to treatment with antibiotics and an appropriate topical corticosteroid. If a lesion is suspected to be infected with herpes simplex virus, treatment with oral aciclovir should be started even if the infection is localised. Topical corticosteroids should be stopped but antiseptics such as povidone iodine can be used and treatment with topical aciclovir may also be considered.

If eczema herpeticum (widespread herpes simplex virus) is suspected, treatment with systemic aciclovir should be started immediately and the person should be referred for same-day specialist dermatological advice. If secondary bacterial infection is also suspected, treatment with appropriate systemic antibiotics should also be started. If eczema herpeticum involves the skin around the eyes, the person should be treated with systemic aciclovir and should be referred for same-day ophthalmological and dermatological advice.

Patients with atopic eczema (or their carers) should be offered information on how to recognise eczema herpeticum. Signs of eczema herpeticum are:

- Areas of rapidly worsening, painful eczema
- Clustered blisters consistent with early-stage cold sores
- Punched-out erosions (circular, depressed, ulcerated lesions) usually 1-3 millimetres that are uniform in appearance (these may coalesce to form larger areas of erosion and crusting)
- Possible fever, lethargy or distress.

Tips for living with eczema (National Eczema Society)

The following simple tips can make a huge difference to the lives of people with eczema and may improve compliance with, what can be, a complicated treatment regime:

- Find the right emollient – patients are more likely to use it frequently.
- Always do a patch test for any new product. Apply the new product to a small area of skin on the inner arm and leave for 24 hours to check for adverse reactions.
- Ensure the patient has small packs of their creams to carry around and apply frequently.
- Large tubs can be kept at home. Pump packs will help to avoid contamination.
- Emollients should be dabbed onto the skin then stroked lightly in the direction of the hair growth.
- If the skin is particularly hot and itchy, it may be helpful to cool creams or lotions in a fridge before applying them to the skin. This cannot be done with most ointments which will become too hard to use.
- Advise patients to have extra supplies of emollients to be kept wherever they may need them, e.g. at work.
- Apply emollient before doing anything which could aggravate the eczema to help act as a barrier and to prevent skin drying out.
- Many people with eczema find that man-made fibres and wool irritate the skin.

Prescribing points: Infected atopic eczema

- NICE advises that people with atopic eczema (or their carers) should obtain new supplies of their usual topical atopic eczema medications after treatment for infected atopic eczema because products in open containers can become contaminated with micro-organisms and act as a source of infection.
- Continue treatment with topical corticosteroids and emollients while taking antibiotics.
- Healthcare professionals should only take swabs from infected lesions of atopic eczema if they suspect micro-organisms other than Staphylococcus aureus to be present, or if they think antibiotic resistance is relevant.

The Commission on Human Medicines has advised that flucloxacillin has been associated with a very small increased risk of hepatic disorders (hepatitis and cholestatic jaundice). Hepatic reactions may occur up to two months after treatment with flucloxacillin has stopped. Risk factors include treatment for more than 14 days and increasing age. The dose and route of administration do not appear to affect this risk. Avoid flucloxacillin in people with hepatic impairment, or a history of hepatic dysfunction associated with flucloxacillin.
## Summary: Managing Atopic Eczema

<table>
<thead>
<tr>
<th>Description</th>
<th>Managing an acute flare</th>
<th>Maintaining skin between flares</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mild Eczema</strong></td>
<td>• Areas of dry skin</td>
<td>Emollients are the mainstay of treatment for mild flares. Prescribe generous amounts and advise frequent and liberal use. Consider prescribing topical hydrocortisone for areas of red skin. Continue treatment for 48 hours after the flare has been controlled.</td>
</tr>
<tr>
<td></td>
<td>• With or without small areas of redness</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Infrequent itching</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Moderate eczema</strong></td>
<td>• Areas of dry skin</td>
<td>Advise frequent and liberal use of emollients (i.e. more than usual). A moderate potency topical corticosteroid should be used on inflamed areas. Treatment should be continued for 48 hours after signs and symptoms have resolved.</td>
</tr>
<tr>
<td></td>
<td>• Frequent itching</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Redness (with or without excoriation and localised skin thickening)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Severe eczema</strong></td>
<td>• Widespread areas of dry skin</td>
<td>• Advise frequent and liberal use of emollients (i.e. more than usual).</td>
</tr>
<tr>
<td></td>
<td>• Incessant itching</td>
<td>• A potent topical corticosteroid should be used on inflamed areas.</td>
</tr>
<tr>
<td></td>
<td>• Redness (with or without excoriation, extension skin thickening, bleeding, oozing, cracking, and alteration of pigmentation)</td>
<td>• Treatment should be continued for 48 hours after signs and symptoms have resolved.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Consider prescribing a sedating antihistamine if itching is severe and affecting sleep (maximum 2 week course).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Consider prescribing a short course of oral corticosteroids if there is severe, extensive eczema causing psychological distress.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Infected eczema</strong></td>
<td>Most common causative organisms are Staphylococcus aureus or Streptococcus species. Characteristics include weeping, pustules, crusts, failure to respond to treatment, rapidly worsening eczema, and fever or malaise.</td>
<td>Extensive areas of infected eczema require an oral antibiotic:</td>
</tr>
<tr>
<td></td>
<td>If infected eczema co-exists with a flare, concomitant treatment at the appropriate treatment step will be required. See above.</td>
<td>• Flucloxacillin is the first-line choice.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• A macrolide, e.g. clarithromycin, if penicillins are contraindicated.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>If localised areas of infection, consider a topical antibiotic:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Creams or ointments containing antibiotics can be used as separate products or combined with a corticosteroid.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Topical antibiotics should not be used for longer than 2 weeks.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Avoid trigger factors where possible, and give advice on preventing infection.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Encourage the frequent and liberal use of emollients during periods where the skin is clear.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Prescribe corticosteroids to control areas of skin prone to flares. Consider: a step down approach (prescribe the lowest potency and amount of steroid necessary to control the condition) or, weekend therapy (use of topical corticosteroids on two consecutive days, once a week)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Topical calcineurin inhibitors are a second-line option.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Provide education on recognising the early signs and symptoms of a flare. Should this occur, advise immediate and aggressive treatment, using an agreed stepped-care plan.</td>
</tr>
</tbody>
</table>

### Websites

- British Association of Dermatologists – [www.bad.org.uk](http://www.bad.org.uk)
- Primary Care Dermatology Society - [www.pcds.org.uk](http://www.pcds.org.uk)
- British Dermatology Nursing Group - [www.bdng.org.uk](http://www.bdng.org.uk)
112. Kelleher M et al. Skin barrier dysfunction measured by transepidermal water loss at 2 days and 2 months predates and predicts atopic dermatitis at 1 year. J Allergy Clin Immunol. 2015 Apr; 135(4): 930-935.e1


© Queen’s Printer and Controller of HMSO 2010
This material was prepared on behalf of the Northern Ireland Health and Social Care Board by:
Lynn Keenan BSc(Hons) MSc MPS
(2016 Review by Michelle O’Prey)
Prescribing Information Pharmacist

COMPASS Unit
Pharmaceutical Department
HSC Business Services Organisation
2 Franklin Street, Belfast
BT2 8DQ.

Any queries on re-use should be directed to Michelle O’Prey (e-mail: michelle.o.prey@hscni.net, telephone 028 9536 9325)

You may re-use this material free of charge in any format or medium for private research/ study, or for circulation within an organisation, provided that the source is appropriately acknowledged. The material must be re-used accurately in time and context, and must NOT be used for the purpose of advertising or promoting a particular product or service for personal or corporate gain.

Please note that every effort has been made to ensure that the content of the COMPASS Therapeutic Notes is accurate at the time of publication. Readers are reminded that it is their responsibility to keep up-to-date with any changes in practice.

With thanks to the following for kindly reviewing this document:
Dr D O’Kane, Consultant Dermatologist, Royal Victoria Hospital and Royal Belfast Hospital for Sick Children, BHSCT
Dr P O’Hare, General Practitioner & Hospital Practitioner in Dermatology, Altnagelvin Hospital, WHST

The editorial panel for this edition of COMPASS Therapeutic Notes:
Dr Bryan Burke (General Practitioner)
Miss Veranne Lynch (NICE Medicines and Prescribing Centre Associate / Pharmacy Advisor HSCB)
Dr Ursula Mason (General Practitioner)
Miss Joanne McDermott (Pharmacy Advisor, HSCB)
Mrs Stephanie Sloan (Community Pharmacist)
COMPASS Therapeutic Notes are circulated to GPs, nurses, pharmacists and others in Northern Ireland. Each issue is compiled following the review of approximately 250 papers, journal articles, guidelines and standards documents. They are written in question and answer format, with summary points and recommendations on each topic. They reflect local, national and international guidelines and standards on current best clinical practice. Each issue is reviewed and updated every three years. Each issue of the Therapeutic Notes is accompanied by a set of assessment questions. These can contribute 2-3 hours towards your CPD/CME requirements. Submit your completed MCQs to the appropriate address (shown below) or complete online at www.medicinesni.com. Assessment forms for each topic can be submitted in any order and at any time.

If you would like extra copies of Therapeutic Notes and MCQ forms for this and any other topic you can:
Visit the COMPASS Web site: www.medicinesni.com or www.hscbusiness.hscni.net/services/2163.htm
or
Email your requests to: compass.team@hscni.net
or
Phone the COMPASS Team on: 028 9536 3801

You can now complete your COMPASS multiple choice assessment questions and print off your completion certificate online:

• Doctors and nurses should submit their answers at: www.medicinesni.com
• Pharmacists should submit their answers at: www.nicpld.org

Are you a
Pharmacist? [ ] Community [ ] Hospital [ ] Other (please specify) _________________
GP? [ ] Enter your cipher number: ____________
Nurse? [ ] Enter your PIN number: __________
Title: Mr/Mrs/Miss/Ms/Dr
Surname: __________________ First name: __________________
Address: ________________________________________________
________________________________________________________
Postcode: ____________________________________________

GPs and Nurses:
Complete the form overleaf and return to:
COMPASS Unit
Family Practitioner Services
HSC Business Services Organisation
2 Franklin Street
Belfast
BT2 8DQ

Pharmacists:
Complete the form overleaf and return to:
Northern Ireland Centre for Pharmacy Learning & Development
FREEPOST NICPLD
Belfast BT9 7BL
COMPASS THERAPEUTIC NOTES ASSESSMENT
Management of Atopic Eczema in Primary Care

For copies of the Therapeutic Notes and assessment forms for this and any other topic please visit: [www.medicinesni.com](http://www.medicinesni.com) or [www.hscbusiness.hscni.net/services/2163.htm](http://www.hscbusiness.hscni.net/services/2163.htm).

Successful completion of these assessment questions equates with 2 hours Continuing Professional Development time. Circle your answer TRUE (T) or FALSE (F) for each question. When completed please post this form to the relevant address shown overleaf. Alternatively, you can submit your answers online:

- **Doctors and nurses** should submit their answers at: [www.medicinesni.com](http://www.medicinesni.com)
- **Pharmacists** should submit their answers at: [www.nicpld.org](http://www.nicpld.org)

---

1. **In the management of atopic eczema:**
   - a. Mild atopic eczema can sometimes be managed with topical emollients alone for the most part.  
     - T F
   - b. Early application of topical steroids may prevent a flare from worsening.  
     - T F
   - c. The majority of patients can be managed successfully in primary care.  
     - T F
   - d. Liberal use of topical emollients is the cornerstone of the management of atopic eczema.  
     - T F

2. **Emollients:**
   - a. Patients can cease to use their emollient when their eczema is well controlled.  
     - T F
   - b. An emollient is applied by rubbing a generous amount of the product into the affected area(s).  
     - T F
   - c. An adult whose both legs are affected by atopic eczema will require about 200 grams of emollient per week.  
     - T F
   - d. Use of emollients in atopic eczema is underpinned by a robust evidence base.  
     - T F

3. **Topical corticosteroids in atopic eczema**
   - a. The potency of a topical steroid is a measure of its ability cause vasoconstriction rather than its clinical effectiveness.  
     - T F
   - b. Clobetasol is a topical corticosteroid of moderate potency.  
     - T F
   - c. Topical corticosteroids should be applied before emollients so the steroid is not diluted on the skin.  
     - T F
   - d. It is usually adequate to apply a topical corticosteroid once a day.  
     - T F

4. **Topical calcineurin inhibitors (tacrolimus and pimecrolimus)**
   - a. Tacrolimus is as effective as moderately potent topical steroids.  
     - T F
   - b. Pimecrolimus is as effective as moderately potent topical steroids.  
     - T F
   - c. Tacrolimus can be applied within 10-15 minutes of applying an emollient.  
     - T F
   - d. Pimecrolimus can be applied immediately after applying an emollient.  
     - T F

5. **Infection and atopic eczema**
   - a. Failure to respond to treatment, pustules, crusts, fever, or malaise may be signs that eczema is infected.  
     - T F
   - b. Use of a topical antimicrobial cream or ointment could be considered for localised areas of infected eczema.  
     - T F
   - c. Once a patient commences an oral antibiotic, their topical corticosteroids should be stopped.  
     - T F
   - d. If infection co-exists with a flare of atopic eczema consider stepping up the topical corticosteroid potency until the flare is controlled.  
     - T F